Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer
In recent years, squamous non-small cell lung cancer (NSCLC) didn’t progress much in chemotherapy or target therapy. However, immunotherapy has made breakthroughs in treating squamous NSCLC. Immunotherapy includes two main broad classes of immune checkpoint inhibitors and therapeutic vaccines. Immun...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2016-10-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.09 |
| _version_ | 1818413681452515328 |
|---|---|
| author | Shouzheng WANG Junling LI |
| author_facet | Shouzheng WANG Junling LI |
| author_sort | Shouzheng WANG |
| collection | DOAJ |
| description | In recent years, squamous non-small cell lung cancer (NSCLC) didn’t progress much in chemotherapy or target therapy. However, immunotherapy has made breakthroughs in treating squamous NSCLC. Immunotherapy includes two main broad classes of immune checkpoint inhibitors and therapeutic vaccines. Immune checkpoint inhibitors, including anti cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and anti programmed death receptor 1 (PD-1) antibodies, have been tested in the phase II/III clinical trials and have demonstrated promising outcomes. Immunotherapy will become an important treatment for squamous NSCLC. |
| first_indexed | 2024-12-14T11:07:04Z |
| format | Article |
| id | doaj.art-e8c6f15140804e81ab497e22ad896402 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-14T11:07:04Z |
| publishDate | 2016-10-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-e8c6f15140804e81ab497e22ad8964022022-12-21T23:04:29ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872016-10-011910pagepage10.3779/j.issn.1009-3419.2016.10.09Progress in Immunotherapy for Squamous Non-small Cell Lung CancerShouzheng WANG0Junling LI1National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
Beijing 100021, ChinaNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
Beijing 100021, ChinaIn recent years, squamous non-small cell lung cancer (NSCLC) didn’t progress much in chemotherapy or target therapy. However, immunotherapy has made breakthroughs in treating squamous NSCLC. Immunotherapy includes two main broad classes of immune checkpoint inhibitors and therapeutic vaccines. Immune checkpoint inhibitors, including anti cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and anti programmed death receptor 1 (PD-1) antibodies, have been tested in the phase II/III clinical trials and have demonstrated promising outcomes. Immunotherapy will become an important treatment for squamous NSCLC.http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.09Lung neoplasmsImmunotherapyCheckpoint inhibitorsTumour vaccines |
| spellingShingle | Shouzheng WANG Junling LI Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer Chinese Journal of Lung Cancer Lung neoplasms Immunotherapy Checkpoint inhibitors Tumour vaccines |
| title | Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer |
| title_full | Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer |
| title_fullStr | Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer |
| title_full_unstemmed | Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer |
| title_short | Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer |
| title_sort | progress in immunotherapy for squamous non small cell lung cancer |
| topic | Lung neoplasms Immunotherapy Checkpoint inhibitors Tumour vaccines |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.09 |
| work_keys_str_mv | AT shouzhengwang progressinimmunotherapyforsquamousnonsmallcelllungcancer AT junlingli progressinimmunotherapyforsquamousnonsmallcelllungcancer |